Result of General Meeting

RNS Number : 8255K

Hemogenyx Pharmaceuticals PLC

06 January 2021

 

6 January 2021

Hemogenyx Pharmaceuticals plc 

("Hemogenyx Pharmaceuticals" or the "Company")

Result of General Meeting

Hemogenyx Pharmaceuticals plc is pleased to announce that, at the General Meeting held earlier today, all resolutions were duly passed. The numbers of votes for each resolution are presented below.

General Meeting Voting Results

Ordinary Resolutions	Votes for	% of votes cast for	Votes Against	% of votes cast against	Total votes cast	Total votes cast as % of ISC (1)	Votes with-held (2)
1. To grant the Directors the authority to issue the Convertible Loan Notes	152,836,161	99.93%	110,000	0.07%	152,946,161	35.27%	10,000
2. To authorise the allotment of shares and the right to subscribe for or convert any security into shares	152,836,161	99.93%	110,000	0.07%	152,946,161	35.27%	10,000
Special Resolutions	Votes for	% of votes cast for	Votes against	% of votes cast against	Total votes cast	Total votes cast as % of ISC (1)	Votes with-held (2)
3. To disapply statutory pre-emption provisions	152,836,161	99.93%	110,000	0.07%	152,946,161	35.27%	10,000

(1)  The Company's issued share capital ("ISC") on 4 January 2021, being the date on which members had to be entered in the register of members of the Company in order to be entitled to attend and vote at the meeting, was 433,636,255 ordinary shares.

(2)  A 'vote withheld' in respect of any resolution is not a vote in law and is not counted in the calculation of the proportion of the votes for and against it.

Enquiries:

Hemogenyx Pharmaceuticals plc	https://hemogenyx.com
Dr Vladislav Sandler, Chief Executive Officer & Co-Founder	[e-mail]
Peter Redmond, Director	[e-mail]
SP Angel Corporate Finance LLP	Tel: [phone]
Matthew Johnson, Vadim Alexandre, Adam Cowl
Peterhouse Capital Limited	Tel: [phone]
Lucy Williams, Duncan Vasey, Charles Goodfellow

 

END

 

 

ROMEQLFBFFLEBBF